BSE - Free Realtime Quote INR

Cipla Limited (CIPLA.BO)

1,346.05 -1.60 (-0.12%)
As of 1:34 PM GMT+5:30. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Umang Vohra B.E., M.B.A. MD, Global CEO & Executive Director 174.9M -- 1971
Dr. Raju Sunil Mistry M.A., Ph.D. President & Global Chief People Officer -- -- 1965
Mr. Pradeep Bhadauria President & Chief Scientific Officer -- -- --
Mr. Ashish Adukia Global Chief Financial Officer -- -- --
Mr. Dinesh Ramniranjan Jain Senior VP & Head of Corporate Finance -- -- --
Ms. Geena V. Malhotra Global Chief Technology Officer -- -- --
Mr. Naveen Bansal Head of Investor Relations -- -- --
Mr. Rajendra Kumar Chopra Compliance Officer & Company Secretary 15.3M -- --
Ms. Heena Kanal Senior Vice-President of Corporate Communications -- -- --
Mr. Anurag Mishra Head of Cipla Foundation -- -- --

Cipla Limited

Cipla House
Peninsula Business Park Ganpatrao Kadam Marg Lower Parel
Mumbai, 400013
India
91 22 2482 6000 https://www.cipla.com
Sector: 
Healthcare
Full Time Employees: 
32,323

Description

Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Corporate Governance

Cipla Limited’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 1; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jul 21, 2023
    Ex-Dividend Date

Upcoming Events

May 10, 2024
Cipla Limited Earnings Call

Related Tickers